Recce Pharmaceuticals seeks $10m capital injection (opens original article in a new tab)
Recce Pharmaceuticals, a biotech firm developing treatments for antimicrobial-resistant superbugs, is seeking a $10 million capital raise to advance its clinical trials and support a new licensing agreement.
- Recce Pharmaceuticals seeks $10m capital injection to complete clinical trials
- Company develops therapies for antimicrobial-resistant superbugs
- Company has new licensing agreement
Conversation
No comments yet
Threaded discussion is coming next — this is where the community conversation about this story will live.